2-(trideca-6,12-diynyloxy)tetrahydropyran | 220978-43-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 2-(trideca-6,12-diynyloxy)tetrahydropyran
• 英文别名: 2-Trideca-6,12-diynoxyoxane
• CAS: 220978-43-8
• 化学式: C₁₈H₂₈O₂
• 分子量: 276.419
• InChiKey: PZMCPWMSJFFWLF-UHFFFAOYSA-N

物化性质

• 沸点：
  387.2±42.0 °C(Predicted)
• 密度：
  0.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.29
• 重原子数：
  20.0
• 可旋转键数：
  9.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  18.46
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  2-(trideca-6,12-diynyloxy)tetrahydropyran 在 六甲基磷酰三胺 、 sodium tetrahydroborate 、 正丁基锂 、 乙二胺 作用下， 生成 (6Z,12Z)-6,12-hexadecadienoic acid
  参考文献：
  名称：

  IONIZABLE CATIONIC LIPIDS

  摘要：

  本公开提供了可用作离子化阳离子脂质体的化合物。这些离子化阳离子脂质体可用于制备脂质纳米粒子，以将治疗性核酸传递到细胞中。改进了阳离子离子化脂质体的稳定性，以防止在储存过程中发生氧化降解。

  公开号：

  US20220162521A1
• 作为产物：
  描述：

  3,4-二氢-2H-吡喃 在 六甲基磷酰三胺 、 正丁基锂 作用下， 生成 2-(trideca-6,12-diynyloxy)tetrahydropyran
  参考文献：
  名称：

  IONIZABLE CATIONIC LIPIDS

  摘要：

  本公开提供了可用作离子化阳离子脂质体的化合物。这些离子化阳离子脂质体可用于制备脂质纳米粒子，以将治疗性核酸传递到细胞中。改进了阳离子离子化脂质体的稳定性，以防止在储存过程中发生氧化降解。

  公开号：

  US20220162521A1

文献信息

• Diastereoselective Cobalt-Mediated [2 + 2 + 2] Cycloadditions of Substituted Linear Enediynes Phosphine Oxides:  Scope and Limitations
  作者：Franck Slowinski、Corinne Aubert、Max Malacria

  DOI：10.1021/jo026212r

  日期：2003.1.1

  Variously substituted linear enediynes phosphines oxides possessing the double bond at either the terminal or internal position and with the phosphine oxide appended onto the alkyne or the alkene terminus have been prepared. Their cobalt(I)-mediated cyclizations produce the eta(4)-complexed tricyclic compounds in high yields. The endo/exo selectivity depends on both the position of the phosphine oxide

  制备了在末端或内部位置均具有双键并且将氧化膦附接至炔烃或烯烃末端的各种取代的线性烯二炔膦氧化物。他们的钴（I）介导的环化以高收率生产出eta（4）络合的三环化合物。内/外选择性取决于烯二炔上氧化膦的位置和系链中双键的位置。对于手性氧化膦，观察到一定程度的诱导，并且取决于磷原子上的取代基，非对映选择性可以达到74％。迄今为止，这是报道的建立立体生成中心的环化反应的最高水平。关于我们所有的结果，
• Study of the Diastereoselectivity of Cobalt-Mediated [2+2+2] Cycloadditions of Substituted Linear Enediyne Esters
  作者：Franck Slowinski、Corinne Aubert、Max Malacria

  DOI：10.1002/1099-0690(200109)2001:18<3491::aid-ejoc3491>3.0.co;2-3

  日期：2001.9

  preparation of substituted linear enediyne esters bearing the double bond either at the terminal or at internal position and the ester substituent either at the alkyne or at the alkene terminus is presented. Their cobalt(I)-mediated [2+2+2] cyclizations produce the η4-complexed tricyclic compounds in very good yields. The endo/exo selectivity depends on the position of the ester in the enediyne, but the

  介绍了在末端或内部位置带有双键并且在炔烃或烯烃末端带有酯取代基的取代的线性烯二炔酯的制备。它们的钴 (I) 介导的 [2+2+2] 环化以非常好的产率产生了 η4 络合的三环化合物。内/外选择性取决于酯在烯二炔中的位置，但环化可以是完全非对映选择性的。研究了带有手性酯的烯二炔环化过程中的不对称诱导；然而，非对映体过量是低的。
• Improvement of the diastereoselectivity of the cobalt-mediated [2+2+2] cycloaddition of substituted linear enediynes
  作者：Franck Slowinski、Corinne Aubert、Max Malacria

  DOI：10.1016/s0040-4039(98)02483-6

  日期：1999.1

  The level of the diastereoselectivity of the cobalt-mediated [2+2+2] cyclization of linear enediynes was improved compared to that reported in the literature by substituting the triple or the double bond with ester, phosphine oxide or sulfoxide groups.

  通过用酯，氧化膦或亚砜基团取代三键或双键，与文献报道的相比，钴介导的线性二烯炔的[2 + 2 + 2]环化的非对映选择性水平得到提高。
• Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof
  申请人：Akagera Medicines, Inc.

  公开号：US20220411394A1

  公开（公告）日：2022-12-29

  The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.
• [EN] LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS, AND RELATED METHODS OF USE<br/>[FR] NANOPARTICULES LIPIDIQUES UTILISÉES POUR L'ADMINISTRATION D'ACIDES NUCLÉIQUES, ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：[en]AKAGERA MEDICINES, INC.

  公开号：WO2022115645A1

  公开（公告）日：2022-06-02

  The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with themin vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.